Omeros Corporation

$18.23 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Omeros Corporation

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Stock Analysis

last close $17.71
1-mo return -2.2%
3-mo return 10.6%
avg daily vol. 548.01T
52-week high 25.46
52-week low 9.25
market cap. $1.1B
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $74M
inst own. 56.3%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist